This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Astellas Pharma Gmbh, Riken Corporation. Active years: 2023.
Company Filing History:
1 out of 424 
1 out of 889 
Years Active: 2023
Title: Masayuki Kanki: Innovator in Cancer Treatment
Introduction
Masayuki Kanki is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on utilizing artificial adjuvant cells to enhance the effectiveness and safety of cancer therapies.
Latest Patents
Masayuki Kanki holds a patent for a method for treating cancer using artificial adjuvant cells (aAVC). This invention addresses the problem of providing an effective and safe method for treating or preventing cancer. The solution involves identifying suitable ranges for the dose of α-GalCer loaded on the aAVC cell surface. The pharmaceutical composition comprising aAVC is designed to ensure both effectiveness and safety in cancer treatment.
Career Highlights
Throughout his career, Kanki has worked with prominent companies in the pharmaceutical industry, including Astellas Pharma GmbH and Riken Corporation. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.
Collaborations
Masayuki Kanki has collaborated with notable colleagues such as Keisuke Ohsumi and Kanako Shimizu. These partnerships have played a crucial role in advancing his research and enhancing the impact of his inventions.
Conclusion
Masayuki Kanki's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work continues to inspire advancements in the field of medical research and therapy.